Asset Details
Do you wish to reserve the book?
Sequential targeting of PI3Kδ and LAG3 as an effective anti-cancer approach
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Sequential targeting of PI3Kδ and LAG3 as an effective anti-cancer approach
Do you wish to request the book?
Sequential targeting of PI3Kδ and LAG3 as an effective anti-cancer approach
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Sequential targeting of PI3Kδ and LAG3 as an effective anti-cancer approach
2021
Overview
Summary
Emerging studies have demonstrated the potential of PI3Kδ blockade as an immunotherapy for solid tumours. In pre-clinical models, we recently demonstrated that anti-LAG3 immune checkpoint blockade vastly potentiated PI3Kδ-based immunotherapy, enabling successful tumour control in all treated mice.
Publisher
Nature Publishing Group UK,Nature Publishing Group
Subject
/ Animals
/ Biomedical and Life Sciences
/ Class I Phosphatidylinositol 3-Kinases - immunology
/ Comment
/ Drug Resistance, Neoplasm - drug effects
/ Humans
/ Immune Checkpoint Inhibitors - pharmacology
/ Immune Checkpoint Inhibitors - therapeutic use
/ Lymphocyte Activation Gene 3 Protein
/ Mice
/ Oncology
